Pharmacotherapy in neonatal and pediatric extracorporeal membrane oxygenation (ECMO)

Area of Science:

• Pediatric critical care medicine
• Neonatal pharmacology
• Cardiopulmonary support

Background:

• Extracorporeal membrane oxygenation (ECMO) is a vital life-support therapy for severe respiratory or cardiac failure.
• Optimizing patient outcomes relies on managing the primary condition and its complications effectively.
• Appropriate pharmacotherapy is crucial for achieving therapeutic goals in ECMO patients.

Purpose of the Study:

• To review existing pharmacokinetic (PK) and pharmacodynamic (PD) studies of drugs in neonates and children undergoing ECMO.
• To explore potential mechanisms behind altered PK and PD in this population.
• To identify key areas for future research in pediatric ECMO pharmacotherapy.

Main Methods:

• Literature review of published PK and PD studies involving neonates and children on ECMO.
• Analysis of reported drug disposition (volume of distribution, clearance) in pediatric ECMO patients.
• Synthesis of findings to propose underlying mechanisms for altered drug behavior.

Main Results:

• Pharmacokinetic and pharmacodynamic data for drugs in pediatric ECMO patients are scarce.
• Studies consistently indicate altered volume of distribution and clearance for various drugs.
• Significant inter-patient variability in drug handling is observed.

Conclusions:

• Altered drug pharmacokinetics and pharmacodynamics are common in pediatric patients on ECMO.
• Understanding these changes is critical for effective and safe drug administration.
• Further dedicated research is essential to optimize pharmacotherapy and improve outcomes for neonates and children on ECMO.